Phase I/II Trial of the Combination of Midostaurin (PKC412) and 5-Azacytidine for Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome

We investigated the combination of midostaurin and azacitidine (AZA) in patients with AML and high risk MDS. Patients received AZA 75 mg/m(2) on days 1–7 and midostaurin 25 mg bid (in cohort 1 of phase I) or 50 mg bid (in cohort 2 of Phase I and in Phase II) orally on day 8–21 during the first cycle...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Am J Hematol
Main Authors: Strati, Paolo, Kantarjian, Hagop, Ravandi, Farhad, Nazha, Aziz, Borthakur, Gautam, Daver, Naval, Kadia, Tapan, Estrov, Zeev, Garcia-Manero, Guillermo, Konopleva, Marina, Rajkhowa, Trivikram, Durand, Menda, Andreeff, Michael, Levis, Mark, Cortes, Jorge
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4376596/
https://ncbi.nlm.nih.gov/pubmed/25530214
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.23924
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados